Galenicum

Galenicum

Type	Privately held company
ISIN	🆔
Industry	Pharmaceutical
Founded 📆
Founder 👔	Alejandro Ollé, Joaquim Domingo, Erich Büchen
Headquarters 🏙️	Spain, Barcelona
Number of locations	8 (2021)
Area served 🗺️
Products 📟	Paracetamol, Metformin, Atorvastatin, Rosuvastatin, Gliptins, Dermatological, Probiac, Probiasor.
Brands	Galenicum Axium, Galenicum Vitae, Galenicum Derma, Galenicum Food, Galenicum SAG, Protekting, Vetilea
Revenue🤑	€153,000,000 (2020)
Members
Number of employees	>500
🌐 Website	[ ]
📇 Address
📞 telephone

Galenicum is a Spanish pharmaceutical company headquartered in Barcelona. It was founded in 2003, when three young friends decided to undertake and launch a startup in the pharmaceutical sector. At the beginning, its main line of business was based on the trading of active pharmaceutical ingredients (APIs) for generic drug companies in Spain.

Today, it has become a global ecosystem of several businesses within the pharmaceutical, supplements and food ingredients sectors with presence in more than 50 countries.

It has subsidiaries and representative offices in other cities such as Santiago (Chile), Lima (Peru), Medellin (Colombia), Casablanca (Morocco), Miami (USA) and Mexico.

Galenicum covers the entire value chain of the pharmaceutical sector, from the trading of APIs, research and development (R&D), intellectual property (IP), regulatory affairs (RA), production, supply and marketing.

History

Galenicum is a pharmaceutical company founded in 2003 in Barcelona. After four years of trading of APIs, obtaining exclusive distribution rights in Spain from Dr. Reddy's, and investing in R&D, in 2007 Galenicum obtained its first marketing authorisation for generic products in Spain. Two years later, in 2009, Galenicum was granted with its first patent.

The Galenicum Special Ingredients (GSI) business line for food ingredients was incorporated in 2010. Two years later, in 2012 the founders of Galenicum decided to open new offices in Chile, Peru and Brazil. Later on, in 2013, the owners bought a production plant in San Agustín de Guadalix (Madrid), called SAG. This plant previously belonged to the well-known MSD. Also this year, in 2013, Galenicum launched its new business line Galenicum "Vitae". This enabled them to enter a new business model, business-to-consumer, allowing the company to sell medicines under its own brand name mainly in Latin American markets, but with the projection of growing in other countries.

In 2014, after their first 10 years as a company, they received recognition as "Business of the Year" at the European Business Awards. One of the co-founders, Alex Ollé said: "we believed in doing affordable but high quality medicines, accessible to the maximum number of people possible all around the world". And he also highlighted the fundamental work of all the company's human resources, where he said: "thanks to their effort, this dream has come true. "

On the other hand, Adrian Tripp, CEO of the European Business Awards added: "The winners in 2013/2014 are the ten companies highlighted in their countries and industries, and which are modeling the image of European companies, ensuring that Europe maintains its leading position on the global business world." Also, regarding Galenicum's award he said: "Their dedication to research and development, and its consolidated business model, will help Galenicum to multiply their product pipepline by two within the next four years."

In 2015, the new dermatological products business line was added to the company; and a year later, in 2016, the food supplements line, which was added to the ingredients line (GSI).

Galenicum continued to expand to other countries and a very important one was the United States, where the Food and Drug Administration (FDA) approved the first product developed by Galenicum in 2018. Also that same year, they opened a new office in Colombia.

Finally, in 2019, they created the current "Galenicum Ecosystem" to restructure and launch the different business lines and operations. One of the company's strategic business plans is to double its revenues from the creation of the ecosystem until 2024. One year later, in 2020, Galenicum was recognized as one of the best providers in the management of the COVID-19 crisis, and in recognition, the European Investment Bank (EIB) provided them with 20 million euros to support their R&D and growth activities, especially in the areas of diabetes, oncology and central nervous system (CNS). In addition, the Mayor of San Agustín de Guadalix visited the production plant to thank the effort and work made by all its employees during the pandemic.

Also this same year 2020, Galenicum created a new line in its business ecosystem, dedicated to pharmaceuticals for pets, called Vetilea.

In addition, and in order to continue its expansion and expand its investment in R&D, Galenicum purchased a 5,000 square metres industrial building in order to improve its headquarters in Barcelona and be able to continue with the expected growth of the company.

Galenicum and the COVID-19 crisis

This EIB funding also contributes to the European Central Bank's efforts to mitigate the effects of COVID-19 by supporting companies supplying medicines used to treat the virus. Galenicum is one of the leading Spanish and European producers of paracetamol, a first-line medicine for treating symptoms, and metformin, an essential medicine for diabetic patients who are highly vulnerable to COVID-19. This financial support will therefore allow Galenicum to acquire new equipment to expand the capacity and flexibility of SAG (Galenicum's production plant).

European Commissioner for the Economy Paolo Gentiloni said: “Thanks to the Investment Plan for Europe, the EIB has signed a financing agreement with Spanish pharmaceutical company Galenicum that manufactures drugs, including those used to treat the COVID-19 virus. The new funding will allow the company to expand its operations and portfolio of products and services helping for instance patients affected by cancer and diabetes. This EU support comes at the right time when groundbreaking medical research is more important than ever."

And also de EIB Vice-President and responsible for the Bank's operations in Spain, Ricardo Mourinho Félix said: “We are very pleased to sign this agreement with Galenicum to support the research and development strategy of Galenicum, a Spanish leader in the pharmaceutical sector that produces widely used medicines such as paracetamol and metformin, essential for diabetic patients that are most vulnerable to COVID-19. This loan shows the EIB's firm commitment to providing the resources needed to promote investment in innovation in the European pharmaceutical industry, increase its competitiveness and strategic autonomy, and create high quality jobs.”

Global Footprint

Galenicum is a global ecosystem that started locally in Spain. Its headquarters are located in Barcelona together with its R&D centre, while its production plant is in San Agustín de Guadalix (Madrid). With these two main centres, it has managed to expand its business to more than 50 countries by 2020, mainly through its business-to-business operations with other pharmaceutical laboratories around the world.

It also has subsidiaries in Santiago de Chile (Chile), Lima (Peru), Medellín (Colombia), Casablanca (Morocco), Mexico and Miami (United States).

Social Impact and Environment

Powering SAG with Sun

One of the most important natural resource in Spain is the sun, and Galenicum is aware of this. So Galenicum covered the roof of SAG manufacturing with more than 2,000 solar panels to ensure sustainability.

The Hospital Without Pain

Galenicum took part in a project to minimize pain in respect to carrying our small procedures at hospital for children. It was a project created and implemented by the Sant Joan de Déu Hospital (Barcelona), with the main objective to prevent and minimize the pain and discomfort in children when they are subjected to potentially painful clinical procedures.

The Índigo Association

Galenicum works together with the Índigo Association in Kenya to improve its facilities, leading to a better health and hygiene for more than 100 children.

External Links

• Official website
• Galenicum Axium.
• Galenicum Vitae.
• Galenicum Food.
• Galenicum Derma.
• Galenicum SAG.
• Protekting.
• Vetilea.

This article "Galenicum" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Galenicum. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.

📰 Article(s) of the same category(ies)

• Desta Mart
• I.T. Partners Inc.
• Neuraxpharm
• ObsEva SA
• Adventrum
• Glover's Medicated Salt Cake
• Mamool Abdulrahman

---